Lipocine
LPCN
53 hedge funds and large institutions have $94.3M invested in Lipocine in 2016 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 17 increasing their positions, 17 reducing their positions, and 4 closing their positions.
150% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 4
147% more call options, than puts
Call options by funds: $672K | Put options by funds: $272K
13% more funds holding
Funds holding: 47 → 53 (+6)
0% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 17
21% less capital invested
Capital invested by funds: $119M → $94.3M (-$24.5M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
Top Sellers
| 1 |
KCM
Kingdon Capital Management
New York
|
-$1.86M |
| 2 |
Renaissance Technologies
New York
|
-$1.61M |
| 3 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$923K |
| 4 |
VAM
Visium Asset Management
New York
|
-$733K |
| 5 |
ISL
Ingalls & Snyder LLC
New York
|
-$389K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Wells Fargo
San Francisco,
California
| $1K | -$59.4K | -348 | -98% |
|
52
Creative Planning
Overland Park,
Kansas
| $1K | +$1.02K | +6 | New |
|
53
Geode Capital Management
Boston,
Massachusetts
| $903 | -$512 | -3 | -0.1% |
|
|
ISL
54
Ingalls & Snyder LLC
New York
| – | -$389K | -1,773 | Closed |
|
|
EMG
55
Ellington Management Group
Old Greenwich,
Connecticut
| – | -$311K | -1,417 | Closed |
|
56
D.E. Shaw & Co
New York
| – | -$202K | -921 | Closed |
|
|
MC
57
Menta Capital
San Francisco,
California
| – | -$176K | -799 | Closed |
|
LPCN Hedge Fund Activity: Q1 2016 in Review
53 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q1 2016, worth a combined $94.3M — down 21% from $119M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new LPCN positions and 4 closed out — a net gain of 6 holders — while 17 added to existing stakes and 17 trimmed.
The largest buyer was Gilder Gagnon Howe & Co, adding an estimated $1.52M. The largest seller was Kingdon Capital Management, cutting an estimated $1.86M.
- 53 institutional investors held Lipocine (LPCN) as of Q1 2016, up from 47 in Q4 2015.
- Funds reported $94.3M of Lipocine stock for Q1 2016, down 21% quarter-over-quarter.
- 10 funds opened new Lipocine positions in Q1 2016 and 4 closed out, a net change of +6 holders.
- The largest Lipocine buyer in Q1 2016 was Gilder Gagnon Howe & Co, an estimated $1.52M added.
- The largest Lipocine seller in Q1 2016 was Kingdon Capital Management, an estimated $1.86M sold.
Based on aggregated 13F filings for Q1 2016.